文献速递流行病学与生物统计真实世界研究与卫生经济新药、器械与细胞基因治疗研发

低级别毒品犯罪者分流项目的健康结局与成本效果:基于模型的分析

Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
PubMed 文献 · PLoS Med · 2020-10-13

该研究利用微观模拟模型,校准至美国华盛顿州金县,评估低级别毒品犯罪者监狱分流项目在10年内的健康收益与成本效果。结果显示,该项目可减少HIV和HCV发病率、降低注射吸毒者过量死亡及监狱人数,从医疗系统角度ICER为$25,500/QALY,从社会角度为$6,200/QALY,具有成本效果。

要点

  • 分流项目可减少HIV和HCV新发感染及注射吸毒者过量死亡。
  • 从社会角度,分流项目每获得1个QALY仅需$6,200,可能节约成本。
  • 成本效果取决于参与者能否获得社区干预(如针具交换、成瘾治疗和HIV/HCV治疗)。

核心结论

  • 低级别毒品犯罪者分流项目可能具有成本效果,可节约刑事司法系统成本并中度增加医疗成本。
  • 该项目可减少监禁及相关成本,避免过量死亡,并通过减少HIV和HCV传播改善注射吸毒者、非注射吸毒者及更广泛人群的生活质量。

研究设计与样本

  • 研究采用微观模拟模型,校准至美国华盛顿州金县,涵盖HIV和HCV传播、监禁与治疗系统及现有干预(如针具交换和鸦片激动剂治疗)。
  • 模型考虑人群包括注射吸毒者、非注射吸毒者、男男性行为者和较低风险异性恋者,时间跨度为10年,计算贴现终身成本和质量调整生命年(QALY)。

主要发现

  • 10年内,分流项目估计使HIV发病率降低3.4%(95% CI 2.7%-4.0%),HCV发病率降低3.3%(95% CI 3.1%-3.4%)。
  • 项目估计使注射吸毒者中过量死亡减少10.0%(95% CI 9.8%-10.8%),监狱人数减少6.3%(95% CI 5.9%-6.7%)。
  • 仅考虑医疗成本时,ICER为$25,500/QALY(95% CI $12,600-$48,600);纳入监禁成本节约后,ICER改善至$6,200/QALY(95% CI,成本节约至$24,300)。

关键数值与推荐

  • HIV发病率降低3.4%(95% CI 2.7%-4.0%),HCV发病率降低3.3%(95% CI 3.1%-3.4%)。
  • 注射吸毒者过量死亡减少10.0%(95% CI 9.8%-10.8%),监狱人数减少6.3%(95% CI 5.9%-6.7%)。
  • 医疗系统角度ICER为$25,500/QALY(95% CI $12,600-$48,600),社会角度ICER为$6,200/QALY(95% CI,成本节约至$24,300)。

临床怎么用

  • 分流项目可作为减少低级别毒品犯罪者监禁并改善公共健康的策略。
  • 实施分流项目需确保参与者能够获得社区项目,如针具交换、物质使用障碍治疗及HIV和HCV治疗。

局限性

  • 数据可得性有限,分流项目相关数据少于针对物质使用障碍患者的成熟干预。
  • 模型依赖简化假设,如简化医疗和刑事司法系统路径、采用物质使用障碍治疗的平均效力,未包括无家可归、失业和家庭结构破裂相关成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cycles of incarceration, drug abuse, and poverty undermine ongoing public health efforts to reduce overdose deaths and the spread of infectious disease in vulnerable populations. Jail diversion programs aim to divert low-level drug offenders toward community care resources, avoiding criminal justice costs and disruptions in treatment for HIV, hepatitis C virus (HCV), and drug abuse. We sought to assess the health benefits and cost-effectiveness of a jail diversion program for low-level drug offenders. METHODS AND FINDINGS: We developed a microsimulation model, calibrated to King County, Washington, that captured the spread of HIV and HCV infections and incarceration and treatment systems as well as preexisting interventions such as needle and syringe programs and opiate agonist therapy. We considered an adult population of people who inject drugs (PWID), people who use drugs but do not inject (PWUD), men who have sex with men, and lower-risk heterosexuals. We projected discounted lifetime costs and quality-adjusted life years (QALYs) over a 10-year time horizon with and without a jail diversion program and calculated resulting incremental cost-effectiveness ratios (ICERs) from the health system and societal perspectives. We also tracked HIV and HCV infections, overdose deaths, and jail population size. Over 10 years, the program was estimated to reduce HIV and HCV incidence by 3.4% (95% CI 2.7%-4.0%) and 3.3% (95% CI 3.1%-3.4%), respectively, overdose deaths among PWID by 10.0% (95% CI 9.8%-10.8%), and jail population size by 6.3% (95% CI 5.9%-6.7%). When considering healthcare costs only, the program cost $25,500/QALY gained (95% CI $12,600-$48,600). Including savings from reduced incarceration (societal perspective) improved the ICER to $6,200/QALY gained (95% CI, cost-saving $24,300). Sensitivity analysis indicated that cost-effectiveness depends on diversion program participants accessing community programs such as needle and syringe programs, treatment for substance use disorder, and HIV and HCV treatment, as well as diversion program cost. A limitation of the analysis is data availability, as fewer data are available for diversion programs than for more established interventions aimed at people with substance use disorder. Additionally, like any model of a complex system, our model relies on simplifying assumptions: For example, we simplified pathways in the healthcare and criminal justice systems, modeled an average efficacy for substance use disorder treatment, and did not include costs associated with homelessness, unemployment, and breakdown in family structure. CONCLUSIONS: We found that diversion programs for low-level drug offenders are likely to be cost-effective, generating savings in the criminal justice system while only moderately increasing healthcare costs. Such programs can reduce incarceration and its associated costs, and also avert overdose deaths and improve quality of life for PWID, PWUD, and the broader population (through reduced HIV and HCV transmission).

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Bernard CL, Rao IJ, Robison KK, et al. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis. PLoS Med. 2020. PMID: 33048929. doi:10.1371/journal.pmed.1003239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。